BRIEF published on 12/08/2025 at 19:35, 3 months 12 days ago ADOCIA Announces Share and Voting Rights Update Voting Rights Shares Financial Disclosure Diabetes Treatment ADOCIA
PRESS RELEASE published on 12/08/2025 at 19:30, 3 months 12 days ago Inside Information / Other news releases Adocia SA releases total number of shares and voting rights as of December 8th, 2025. Company focuses on innovative therapeutic solutions for diabetes and obesity Voting Rights Shares Diabetes Obesity ADOCIA
BRIEF published on 12/04/2025 at 07:35, 3 months 17 days ago ADOCIA Secures €10 Million Fundraising for Growth Shares Fundraising Investment Biopharmaceutical ADOCIA
PRESS RELEASE published on 12/04/2025 at 07:30, 3 months 17 days ago Inside Information / Other news releases Adocia successfully completes a €10 million fundraising through a capital increase. Proceeds to support technology platform development. Cash runway extended to 2027 Fundraising Capital Increase Cash Runway ADOCIA Technology Platforms
BRIEF published on 11/12/2025 at 07:35, 4 months 9 days ago Adocia Progresse with AdoXLongTM and BioChaperone® Diabetes Patent ADOCIA BioChaperone® AdoXLongTM
PRESS RELEASE published on 11/12/2025 at 07:30, 4 months 9 days ago Inside Information / Other news releases Adocia files patent for AdoXLongTM platform to extend duration of action for peptides in diabetes and obesity treatment. BioChaperone® platform updated with feasibility studies Obesity Treatment Diabetes Treatment Patent Filing ADOCIA AdoXLongTM
BRIEF published on 10/21/2025 at 10:47, 5 months ago Crossing thresholds at ADOCIA Warrants Actions Crossing Thresholds ADOCIA Vester Finance
BRIEF published on 10/15/2025 at 08:50, 5 months 6 days ago Positive results for BioChaperone® Lispro insulin in Phase 3 Clinical Trial Type 1 Diabetes ADOCIA BioChaperone® Tonghua Dongbao
PRESS RELEASE published on 10/15/2025 at 08:45, 5 months 6 days ago Inside Information / Other news releases ADOCIA and Tonghua Dongbao announce positive Phase 3 results for Ultra-Rapid Insulin BioChaperone Lispro in Type 1 Diabetes treatment, showing non-inferior HbA1c reduction and improved blood glucose control post-meal Type 1 Diabetes Phase 3 Results ADOCIA Tonghua Dongbao Ultra-Rapid Insulin
BRIEF published on 07/25/2025 at 08:50, 7 months 27 days ago Adocia and Tonghua Dongbao Report Phase 3 Success for Ultra-Rapid Insulin Diabetes Treatment Clinical Trial Phase 3 Results ADOCIA BioChaperone® Lispro
Published on 03/20/2026 at 21:15, 15 hours 55 minutes ago Earthwise Minerals Announces Private Placement
Published on 03/20/2026 at 13:30, 23 hours 40 minutes ago Unusual Machines Announces Pricing of Approximately $150 Million Public Offering of Common Stock
Published on 03/20/2026 at 12:30, 1 day ago CANEX Metals Announces the Numbers of Gold Basin Shares Taken up by Canex Metals
Published on 03/20/2026 at 22:45, 14 hours 25 minutes ago Investor Alert: Berger Montague (Canada) PC represents investors that purchased shares of Super Micro Computer, Inc. listed on the CBOE Canada and elsewhere
Published on 03/20/2026 at 21:05, 16 hours 5 minutes ago Fractal EMS Receives ISO/IEC 9001 and 27001 Certifications
Published on 03/20/2026 at 21:05, 16 hours 5 minutes ago Nebius Group announces closing of private offering of convertible senior notes, with aggregate gross proceeds of approximately $4.3 billion
Published on 03/20/2026 at 21:00, 16 hours 10 minutes ago BRP Unveils the Winners of its 6th International Design Challenge
Published on 03/20/2026 at 20:05, 17 hours 5 minutes ago INVESTOR ALERT: Goeasy Ltd. Shareholder Class Action
Published on 03/20/2026 at 19:00, 18 hours 10 minutes ago AXA - Conditions for availability or consultation of information relating to AXA’s Shareholders’ Meeting of April 30, 2026
Published on 03/20/2026 at 18:15, 18 hours 55 minutes ago Publication of AXA’s 2025 Universal Registration Document
Published on 03/20/2026 at 16:57, 20 hours 13 minutes ago Number of shares and voting rights - February 2026 (In French only)
Published on 03/19/2026 at 18:00, 1 day 19 hours ago Filing of the 2025 Universal Registration Document
